PureTech Health Stock

PureTech Health EBIT Margin

Delisted·Jun 19, 2026

The EBIT Margin (Operating Margin) of PureTech Health (PRTC.L) as of Jul 29, 2026 is -2,818.87 %. In the previous year, EBIT Margin (Operating Margin) was -4,390.36 % — a change of -35.79% (higher).

EBIT Margin

-2,818.87 %

YoY

-35.79%

Last updated:

EBIT Margin (Operating Margin) of PureTech Health is 2026 -2,818.87 % . EBIT Margin (Operating Margin) of PureTech Health was 2025 -4,390.36 % . It decreases by -35.79% higher compared to the previous year.

For PureTech Health, the operating (EBIT) margin of -2,818.9% is down versus -1,015.5% a few years ago.

Access this data via the Eulerpool API

PureTech Health Stock analysis

What does PureTech Health do? PureTech Health is an innovative company specializing in the development of novel medical therapies and solutions. The company was founded in 2002 by Daphne Zohar and is headquartered in Boston, USA. PureTech Health is listed on the London Stock Exchange and has become one of the leading biotech companies in recent years. The company's business model is based on identifying medical needs and developing new products and therapies to meet those needs. It utilizes cutting-edge technologies to work quickly and effectively. Research and development are closely linked in an iterative process. PureTech Health's main focus is oncology, specifically developing immune-oncology therapies that target the patient's immune system to strengthen their body's defense against cancer cells. The company has also developed an innovative drug discovery system that combines nanotechnology and artificial intelligence. Another focus area for PureTech Health is gastroenterology. The company has developed a novel technology that selectively releases medical substances in the intestine, allowing targeted treatment of gastrointestinal diseases. PureTech Health has also developed a new method for diagnosing colorectal cancer based on the identification of bacteria in feces. In the field of neuropsychiatric disorders, the company has promising research results. It has developed a new technology that enables targeted manipulation of the central nervous system, allowing for the treatment of conditions such as depression, anxiety disorders, and ADHD. To this end, PureTech Health has developed a novel nasal spray that delivers the active ingredients directly to the brain. Biosensing is another area of focus for PureTech Health. The company has developed a novel technology that allows for the measurement of medical parameters such as blood sugar, cholesterol, and blood pressure. The sensors are available in the form of patches or other wearable devices and are easy and convenient to use. This technology is intended to help older people and those with chronic illnesses better monitor their health. Overall, PureTech Health is an innovative biotech company that is constantly seeking novel medical solutions. It operates in various areas and has promising products and therapies in the pipeline. With its close integration of research and development, PureTech Health is able to quickly and flexibly respond to market changes. With strong management and an experienced team, the company is well-positioned for further growth in the coming years. PureTech Health is one of the most popular companies on Eulerpool.

Frequently Asked Questions about PureTech Health stock

EBIT Margin (Operating Margin) of PureTech Health is -2,818.87 % in 2026.

Access this data via the Eulerpool API

Margins — PureTech Health

All Key Metrics — PureTech Health